Home
/
Treatment
/
metavert, N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide

metavert, N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide

	metavert, N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide
Trade Name
Orphan Indication	Pancreatic Cancer
USA Market Approval	USA
USA Designation Date	2016-07-06 00:00:00
Sponsor	Avenzoar Pharmaceuticals, Inc.;662 Encinitas Blvd, Suite 248;Encinitas, California, 92024

Related Access Program

Baxalta – Pancreatic Cancer University of Roma La Sapienza – Pancreatic Cancer University of Roma La Sapienza – Pancreatic Cancer